Dernières nouvelles pour PACS Group (NYSE:PACS) Stock

PACS Group

PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.

PACS Group Inc

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. The company reported quarterly sales of $122.751 million which missed the analyst consensus estimate of $125.853 million by 2.47 percent. This is a 3.99 percent decrease over sales of $127.854 million the same period last year.

Earnings

Earnings Misses

News

NDLS

Noodles Q3 2024 Adj. EPS $(0.12) Misses $(0.06) Estimate, Sales $122.751M Miss $125.853M Estimate

Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $403.500 million which beat the analyst consensus estimate of $392.440 million by 2.82 percent. This is a 14.34 percent increase over sales of $352.900 million the same period last year.

Earnings Beats

Crane NXT Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $403.500M Beat $392.440M Estimate

Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent.

Brookdale Senior Living Q3 2024 Adj. EPS $(0.22) Misses $(0.17) Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

Guidance

VCYT

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

CLNE

Clean Energy Fuels Sees FY24 Adj. EBITDA $62M-$72M

VIZIO Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZIO#NYSE">VZIO</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.02) by 105 percent. The company reported quarterly sales of $444.70 million which beat the analyst consensus estimate of $443.80 million by 0.20 percent. This is a 4.34 percent increase over sales of $426.20 million the same period last year.

VZIO

VIZIO Holding Q3 2024 GAAP EPS $0.00 Beats $(0.02) Estimate, Sales $444.70M Beat $443.80M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) raises FY2025 sales outlook from $715.00 million-735.00 million to $737.00 million-739.00 million.

RAMP

LiveRamp Holdings Raises FY2025 Sales Guidance from $715.00M-735.00M to $737.00M-739.00M

Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $330.99 million which missed the analyst consensus estimate of $346.28 million by 4.42 percent. This is a 8.16 percent increase over sales of $306.03 million the same period last year.

CLOV

Clover Health Investments Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $330.99M Miss $346.28M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) sees Q3 sales of $191.000 million vs $188.55 million estimate.

LiveRamp Holdings Sees Q3 Sales $191.000M vs $188.55M Est

Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 89.66 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $1.39 million which missed the analyst consensus estimate of $1.48 million by 6.01 percent. This is a 30.98 percent increase over sales of $1.06 million the same period last year.

NYXH

Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate

Retail Sales

FTEK

Fuel Tech Inc Announced Orders From New And Existing Customers Totaling ~$2M

e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares are climbing after the company reported its second-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786513/e-l-f-beauty-announces-second-quarter-fiscal-2025-results">details from the report.  </a>
The Details: e.l.f. Beauty reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $301.1 million, which beat the analyst consensus estimate of $285.76 million and is an increase over sales of $215.5 million from the same period last year.
e.l.f. said its gross margin increased approximately 40 basis points to 71%, primarily driven by cost savings, favorable foreign exchange impacts and price increases in the company&#8217;s international markets, partially offset by mix and higher transportation costs.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;Q2 marked another quarter of consistent, category-leading growth. In Q2, we delivered 40% net sales growth, fueled by 195 basis points of market share gains in the U.S. and 91% net sales growth internationally,&#8221; said Tarang Amin, e.l.f. Beauty&#8217;s CEO.
&#8220;This was our 23rd consecutive quarter of both net sales growth and market share gains. We continue to make progress across color cosmetics, skincare and international and believe our unique areas of advantage will fuel our ability to win in fiscal 2025 and beyond,&#8221; Amin added.
Outlook: e.l.f. Beauty raised its fiscal year 2025 net sales outlook to a range of $1.315 billion to $1.335 billion and now sees earnings of between $3.47 and $3.53 per share for the year.
ELF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, e.l.f. Beauty shares are up 13.24% after-hours at $117.95 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Courtesy of E.l.f. Beauty, Inc.

Movers

e.l.f. Beauty Stock Soars After Strong Q2 Earnings Beat: Details

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

CCRN

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

GFL Environmental Q3 2024 Adj. EPS C$0.23 Misses C$0.35 Estimate, Sales C$2.015B Miss C$2.052B Estimate

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. The company reported quarterly sales of $2.653 billion which beat the analyst consensus estimate of $2.485 billion by 6.76 percent. This is a 3.67 percent increase over sales of $2.559 billion the same period last year.

Williams Companies Q3 2024 Adj. EPS $0.43 Beats $0.42 Estimate, Sales $2.653B Beat $2.485B Estimate

CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $36.27 million which missed the analyst consensus estimate of $36.33 million by 0.18 percent. This is a 3.79 percent increase over sales of $34.94 million the same period last year.

CS Disco Q3 Adj $(0.06) Beats $(0.09) Estimate, Sales $36.27M Miss $36.33M Estimate

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) raises FY2024 sales outlook from $1.05 billion-1.13 billion to $1.06 billion-1.13 billion.

Emergent BioSolutions Raises FY2024 Sales Guidance from $1.05B-1.13B to $1.06B-1.13B

Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.57 by 14.65 percent. The company reported quarterly sales of $1.305 billion which beat the analyst consensus estimate of $1.267 billion by 3.01 percent. This is a 10.03 percent increase over sales of $1.186 billion the same period last year.

Marriott Vacations Q3 2024 Adj. EPS $1.80 Beats $1.57 Estimate, Sales $1.305B Beat $1.267B Estimate

TKO Group Holdings Sees FY24 Revenue To Upper End Of $2.67B-$2.745B Vs $2.758B Est.

Buybacks

AMPH

Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date

13:30 EST PACS Group (PACS) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

PACS Group Inc trading resumes

13:25 EST PACS Group (PACS) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-movi...

PACS Group Inc trading halted, volatility trading pause

JPMorgan analyst Lisa Gill resumed coverage of Pacs Group (PACS) with an Overweight rating and $40 price target following a period of restriction. ...

Pacs Group resumed with an Overweight at JPMorgan

Pacs had 183 facilities, or 76%, of its skilled nursing portfolio achieve a 4 or 5 star CMS QM rating. The company's ramping and mature facilities ...

Pacs Group provides preliminary Q3 KPIs

PACS Group postpones Q3 results after short seller's report, sending shares down 30%

Pacs Group (PACS) is down -35.1%, or -$10.38 to $19.16. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

Pacs Group falls -35.1%

Pacs Group (PACS) is down -37.7%, or -$11.12 to $18.41. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

Pacs Group falls -37.7%

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Five Below downgraded, Snowflake upgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Trump Media, broader market surge after Trump wins election: Morning Buzz

Pacs Group (PACS) is down -38.9%, or -$11.49 to $18.05. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

Pacs Group falls -38.9%

AAPL

ARDT

AVDX

CBOE

CELH

CTKB

EXAS

FIVE

HNDAF

HNHAF

HNHPF

IRBT

MASI

NTDOF

NTDOY

OSCR

PACS

PLNT

PODD

RMBS

RVLV

SMCI

SNOW

STLA

TEVA

TNDM

TNGX

TRMB

Legal

Press Releases

Barrack, Rodos & Bacine Is Investigating PACS Group Inc.

The Law Offices of Frank R. Cruz Announces Investigation of PACS Group, Inc. (PACS) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against PACS Group, Inc. (PACS)

PACS INVESTIGATION NOTICE: Investigation Launched into PACS Group, Inc. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

PACS GROUP ALERT: Bragar Eagel & Squire, P.C. is Investigating PACS Group, Inc. on Behalf of PACS Group Stockholders and Encourages Investors to Contact the Firm

PACS Group Provides Preliminary Third Quarter Operational Metrics

PACS STOCK REPORT: PACS Group, Inc. Investors are Notified to Contact BFA Law about the Securities Fraud Investigation after Hindenburg Report (NYSE:PACS)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of PACS Group, Inc. (PACS) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of PACS Group, Inc. (PACS) on Behalf of Investors

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co

Ardent Health Partners, Inc. Common Stock

Ardent Health Partners

Auna

IMAC Hldgs

Brookdale Senior Living Inc. Common Stock

Brookdale Senior Living

Concentra Group Holdings Parent, Inc. Common Stock

Concentra Group Holdings

Community Health Systems, Inc. Common Stock

Community Health Sys

Encompass Health Corporation Common Stock

Encompass Health

Ensign Group

HCA Healthcare

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary

Joint

National HealthCare Corporation Common Stock

National Healthcare

Regional Health Properties, Inc. Common Stock

Regional Health Props

Select Medical Holdings Corporation Common Stock

Select Medical Hldgs

Surgery Partners

Sonida Senior Living

SunLink Health Systems, Inc. Common Stock

SunLink Health Systems

Tenet Healthcare Corporation Common Stock

Tenet Healthcare

The Oncology Institute, Inc. - Common Stock

Oncology Institute

Universal Health Services, Inc. Common Stock

Universal Health Servs

US Physical Therapy

JP Morgan

Truist Securities

Citigroup

Stephens & Co.

WIIM

PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.

Comments

PACS Group

Actualités

Dernières nouvelles pour PACS Group (NYSE:PACS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL